Pazopanib Hydrochloride
- Product Name
- Pazopanib Hydrochloride
- CAS No.
- 635702-64-6
- Chemical Name
- Pazopanib Hydrochloride
- Synonyms
- Pazopanib hydrochloride;Pazopanib HCl;CS-462;ArMala;786034;GW-786034B;GW786034 HCl;Votrient HCl;Pazopanib HCI;Unii-33Y9anm545
- CBNumber
- CB42495435
- Molecular Formula
- C21H24ClN7O2S
- Formula Weight
- 473.98
- MOL File
- 635702-64-6.mol
Pazopanib Hydrochloride Property
- Melting point:
- >290°C (dec.)
- storage temp.
- Hygroscopic, Refrigerator, under inert atmosphere
- solubility
- Acetonitrile (Slightly), DMSO (Slightly)
- form
- Yellow powder.
- color
- White to Off-White
- Stability:
- Hygroscopic
- InChI
- InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
- InChIKey
- MQHIQUBXFFAOMK-UHFFFAOYSA-N
- SMILES
- CC1N(N=C2C=C(N(C3C=CN=C(NC4C=CC(C)=C(S(=O)(=O)N)C=4)N=3)C)C=CC=12)C.Cl
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H332Harmful if inhaled
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- SML3076
- Product name
- Pazopanib hydrochloride
- Purity
- ≥98% (HPLC)
- Packaging
- 10MG
- Price
- $86.1
- Updated
- 2022/05/15
- Product number
- SML3076
- Product name
- Pazopanib hydrochloride
- Purity
- ≥98% (HPLC)
- Packaging
- 50MG
- Price
- $348
- Updated
- 2022/05/15
- Product number
- CS-0126
- Product name
- PazopanibHydrochloride
- Purity
- 99.84%
- Packaging
- 500mg
- Price
- $420
- Updated
- 2021/12/16
- Product number
- A8347
- Product name
- PazopanibHydrochloride
- Packaging
- 500mg
- Price
- $480
- Updated
- 2021/12/16
- Product number
- CS-0126
- Product name
- PazopanibHydrochloride
- Purity
- 99.84%
- Packaging
- 1g
- Price
- $552
- Updated
- 2021/12/16
Pazopanib Hydrochloride Chemical Properties,Usage,Production
Description
Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is an oral second-generation multitarget TKI developed by GSK and approved for marketing by the FDA in 2009 and the EMA in 2010. It targets the VEGFR, platelet-derived growth factor receptor, and c-kit, key proteins responsible for tumor growth and survival. It is used to treat patients with advanced RCC and advanced soft tissue sarcoma who have experienced chemotherapy. Pazopanib Hydrochloride has a role as an antineoplastic agent, a vascular endothelial growth factor receptor antagonist, a tyrosine kinase inhibitor, and an angiogenesis-modulating agent.
Originator
GlaxoSmithKline (US)
Uses
The Hydrochloride salt of Pazopanib (P210925) a oral angiogenesis inhibitor targeting VEGFR and PDGFR.
Uses
Pazopanib Hydrochloride (GW786034, Votrient, Armala) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.
Uses
Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively - See more at: http://www.selleckchem.com/products/Pazopanib-Hyd
Definition
ChEBI: A hydrochloride salt prepared from equimolar amounts of pazopanib and hydrochloric acid. Used for treatment of kidney cancer.
Definition
The growth of solid tumors is dependent on angiogenesis, the process wherein new capillaries are formed from existing blood vessels. VEGF is one of the most important inducers of angiogenesis and expressed at high levels by most tumors. Hence, the inhibition of VEGF or its receptor signaling system is an attractive target for cancer therapeutics. The most studied and developed inhibitors are monoclonal antibodies that neutralize VEGF (e.g., bevacizumab), anti-VEGF ribozymes (e.g., angiozyme), and small-molecule VEGFR kinase inhibitors (e.g., sunitinib, sorafenib). Pazopanib is the latest VEGFR kinase inhibitor to reach the market. It is indicated for the oral treatment of advanced RCC. The biological functions of the VEGF family are mediated by activation of three structurally homologous tyrosine kinase receptors, VEGFR-1, VEGFR-2, and VEGFR3. In vitro, pazopanib inhibits VEGFR-1, VEGFR-2, and VEGFR-3 with IC50 values of 10, 30, and 47 nM, respectively. In addition, it inhibits several of the closely related tyrosine receptor kinases, including platelet-derived growth-factor receptor β(PDGFR-β), c-kit, and fibroblast growth factor receptor-1 (FGFR1) with IC50 values of 84, 74, and 140 nM, respectively. In human umbilical vein endothelial cells (HUVEC), pazopanib inhibits VEGF-induced proliferation more potently than basic fibroblast growth factor (bFGF)-stimulated proliferation (IC50 = 21 nM vs. 721 nM) and concentration-dependently inhibits VEGF-induced VEGFR-2 phosphorylation (IC50 = 7 nM). It also potently inhibits angiogenesis in Matrigel plug and corneal micropocket assays. The most common adverse events associated with pazopanib were diarrhea, hypertension, hair depigmentation, nausea, anorexia, and vomiting.
brand name
Votrient
Clinical Use
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/b, and c-kit that blocks tumor growth and inhibits angiogenesis. It was approved for renal cell carcinoma by the U.S. Food and Drug Administration in 2009 and is marketed under the trade name Votrient by the drug’s manufacturer, GlaxoSmithKline.
Side effects
Pazopanib is synthesized in five chemical steps starting from 3-methyl-6-nitroindazole, which is converted to the corresponding 2,3-dimethylindazole analog via N-methylation with trimethyloxonium tetrafluoroborate. Subsequent reduction of the nitro group to the amino group using tin chloride followed by condensation with 2,4dichloropyrimidine yields a chloropyrimidinylaminoindazole intermediate. The final two steps leading up to pazopanib consist of an N-methylation reaction using iodomethane and cesium carbonate followed by condensation with 5-amino-2-methylbenzenesulfonamide.
Synthesis
The synthesis of pazopanib begins with methylation of 3-methyl-6- nitroindazole (82) with trimethyl orthoformate in the presence of BF3?¤OEt to give indazole 83 in 65% yield. Reduction of the nitro group was achieved via transfer hydrogenation to give 84 in 97% yield, and this was followed by coupling the aniline with 2,4-dichloropyrimidine in a THF-ethanol mixture at elevated temperature to provide diarylamine 85 in 90% yield. The aniline nitrogen was then methylated using methyl iodide to give 86 in 83% yield prior to coupling with 5-amino-2-methylbenzenesulfonamide (87) and salt formation using an alcoholic solution of HCl to furnish pazopanib hydrochloride (XIV) in 81% yield.
target
VEGFR1
References
[1] Sodeifian, G. et al. “Solubility of pazopanib hydrochloride (PZH, anticancer drug) in supercritical CO2: Experimental and thermodynamic modeling.” The Journal of Supercritical Fluids 55 1 (2022): 0.
[2] “Stability Indicating HPTLC Method Development and Validation for the Estimation of Pazopanib Hydrochloride in Bulk and its Dosage Form.” International Journal of Pharmaceutical Research 18 1 (2020).
[3] K. Kawasaki . “Retrospective Safety Analysis in Advanced Soft Tissue Sarcoma Patients of Pazopanib Hydrochloride.” Annals of Oncology 24 (2013): Page ix38.
[4] Gupta, Amit and Rashmi Dahima. “Application of Simplex Lattice Mixture design and desirability function in the development and Optimization of SEDDS for protein kinase inhibitor-Pazopanib Hydrochloride.” Research Journal of Pharmacy and Technology 83 1 (2023): 0.
Pazopanib Hydrochloride Preparation Products And Raw materials
Raw materials
Preparation Products
Pazopanib Hydrochloride Suppliers
- Tel
- 0514-80939770 13773367191
- Fax
- 0514-82664689
- yzqyyykj@163.com
- Country
- China
- ProdList
- 240
- Advantage
- 55
- Tel
- 0576-89085261 15867635987
- Fax
- 0576-89085262
- jasonhu09@163.com
- Country
- China
- ProdList
- 442
- Advantage
- 50
- Tel
- 0573-0573-87228088 17772796899
- Fax
- 0573-87228088
- triview@triviewbiochem.com
- Country
- China
- ProdList
- 17
- Advantage
- 58
- Tel
- 152-6236-2504 18019700392
- Fax
- QQ3572097758
- clong008@163.com
- Country
- China
- ProdList
- 117
- Advantage
- 58
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2922
- Advantage
- 55
- Tel
- +86-21-20908456
- Fax
- 021-58180499
- sales@BioChemBest.com
- Country
- China
- ProdList
- 6005
- Advantage
- 61
- Tel
- 400-6009262 16621234537
- Fax
- 021-64823266
- chenyj@titansci.com
- Country
- China
- ProdList
- 14103
- Advantage
- 59
- Tel
- +86 (531) 88811783
- Fax
- +86 (531) 55696010 QQ 1762738062
- sales@trio-pharmatech.com (International market)
- Country
- China
- ProdList
- 1856
- Advantage
- 62
- Tel
- 0510-0510-83593305
- Fax
- 0086-510-83593305
- sales@huifeichem.com
- Country
- China
- ProdList
- 104
- Advantage
- 62
- Tel
- 0411-62910999 13889544652
- meilunui@163.com
- Country
- China
- ProdList
- 4727
- Advantage
- 58
View Lastest Price from Pazopanib Hydrochloride manufacturers
- Product
- Pazopanib hydrochloride 635702-64-6
- Price
- US $0.00-0.00/kg
- Min. Order
- 1kg
- Purity
- 99%，single impurity＜0.1
- Supply Ability
- 1 ton
- Release date
- 2023-12-19
- Product
- Pazopanib Hydrochlorid 635702-64-6
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- More Than 99%
- Supply Ability
- 100kg/Month
- Release date
- 2024-07-24
- Product
- Pazopanib HCl 635702-64-6
- Price
- US $80.00/KG
- Min. Order
- 1KG
- Purity
- >99%
- Supply Ability
- 20tons
- Release date
- 2023-03-16